Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 379

1.

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project.

N Engl J Med. 2002 Jun 20;346(25):1937-47.

2.

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.

Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R.

N Engl J Med. 2004 Apr 29;350(18):1828-37.

3.

Gene expression profiling of diffuse large B-cell lymphoma.

Rosenwald A, Staudt LM.

Leuk Lymphoma. 2003;44 Suppl 3:S41-7. Review.

PMID:
15202524
4.

Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients.

Riihijärvi S, Koivula S, Nyman H, Rydström K, Jerkeman M, Leppä S.

Mod Pathol. 2010 May;23(5):686-93. doi: 10.1038/modpathol.2010.43. Epub 2010 Feb 26.

5.

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.

J Clin Oncol. 2008 Oct 1;26(28):4587-94. doi: 10.1200/JCO.2007.15.9277. Epub 2008 Jul 28.

PMID:
18662967
6.

Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.

Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG.

J Natl Cancer Inst. 2002 Jan 2;94(1):26-32.

PMID:
11773279
7.

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6. Epub 2003 Aug 4.

8.

Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.

Hoefnagel JJ, Dijkman R, Basso K, Jansen PM, Hallermann C, Willemze R, Tensen CP, Vermeer MH.

Blood. 2005 May 1;105(9):3671-8. Epub 2004 Aug 12.

9.

Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas.

Muris JJ, Ylstra B, Cillessen SA, Ossenkoppele GJ, Kluin-Nelemans JC, Eijk PP, Nota B, Tijssen M, de Boer WP, van de Wiel M, van den Ijssel PR, Jansen P, de Bruin PC, van Krieken JH, Meijer GA, Meijer CJ, Oudejans JJ.

Br J Haematol. 2007 Jan;136(1):38-47. Epub 2006 Oct 25.

PMID:
17062006
10.

Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.

Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, Kajdacsy-Balla A, Perkins SL.

Am J Surg Pathol. 2004 Apr;28(4):464-70.

PMID:
15087665
11.

CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.

Wilson KS, Sehn LH, Berry B, Chhanabhai M, Fitzgerald CA, Gill KK, Klasa R, Skinnider B, Sutherland J, Connors JM, Gascoyne RD.

Leuk Lymphoma. 2007 Jun;48(6):1102-9.

PMID:
17577773
12.

Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype.

Yoshida S, Nakamura N, Sasaki Y, Yoshida S, Yasuda M, Sagara H, Ohtake T, Takenoshita S, Abe M.

Mod Pathol. 2005 Mar;18(3):398-405.

13.

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.

Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM.

Blood. 2004 Jun 1;103(11):4251-8. Epub 2004 Feb 19.

14.

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.

Eur J Haematol. 2009 May;82(5):364-72. doi: 10.1111/j.1600-0609.2009.01222.x. Epub 2009 Jan 9.

PMID:
19141121
15.

Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.

Jardin F, Ruminy P, Kerckaert JP, Parmentier F, Picquenot JM, Quief S, Villenet C, Buchonnet G, Tosi M, Frebourg T, Bastard C, Tilly H.

Haematologica. 2008 Apr;93(4):543-50. doi: 10.3324/haematol.12251. Epub 2008 Feb 20.

16.

Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study.

Cazals-Hatem D, Lepage E, Brice P, Ferrant A, d'Agay MF, Baumelou E, Brière J, Blanc M, Gaulard P, Biron P, Schlaifer D, Diebold J, Audouin J.

Am J Surg Pathol. 1996 Jul;20(7):877-88.

PMID:
8669537
17.

Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation.

de Leval L, Braaten KM, Ancukiewicz M, Kiggundu E, Delaney T, Mankin HJ, Harris NL.

Am J Surg Pathol. 2003 Sep;27(9):1269-77.

PMID:
12960812
18.

Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.

Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, Prat J, Sierra J.

Ann Hematol. 2006 Sep;85(9):597-603. Epub 2006 Jul 8.

PMID:
16830142
19.

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.

Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack AS.

Blood. 2002 Feb 15;99(4):1136-43.

20.

Supplemental Content

Support Center